deltatrials
Completed PHASE3 NCT00003013

Chemotherapy Plus Surgery in Treating Women With Breast Cancer

European Cooperative Study of Chemotherapy and Surgery Comparing Adjuvant Doxorubicin Followed by CMF vs. Adjuvant Doxorubicin/Paclitaxel Followed by CMF vs. Primary Doxorubicin/Paclitaxel Followed by CMF in Women With Operable Breast Cancer and T>2 cm

Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Conditions Breast Cancer
Interventions CMF regimen conventional surgery cyclophosphamide doxorubicin hydrochloride fluorouracil methotrexate paclitaxel radiation therapy tamoxifen citrate
Updated 6 times since 2017 Last updated: Sep 16, 2013 Started: Oct 31, 1996 Completion: Mar 31, 2009

A PHASE3 clinical study on Breast Cancer, this trial is completed. The trial is conducted by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano and has accumulated 6 data snapshots since 1996. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

6 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Oct 1996

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Barcelona, Spain, Bratislava, Slovakia, Budapest, Hungary, Bydgoszcz, Poland, Krakow (Cracow), Poland, Madrid, Spain, Moscow, Russia, Munich, Germany, Murmansk, Russia, Málaga, Spain and 13 more location s